25 August 2011 -- With high-profile speakers from global biopharmaceutical sector discussing a range of challenging situations, the BIA Global BioLeadership Summit 2011 taking place in Windsor on 6-7 October will provide the essential information needed to build a valuable and successful organisation. There will also be a unique opportunity to input into the BIA’s public affairs policy in 2012.
This board-level focused summit will consist of many thought-provoking discussion sessions covering exits, raising capital, organisation change and increased R&D returns. Sessions on crisis communications, the advantages of virtual business models and maximising the effectiveness of a company’s board will also add to this excellent Chatham house rule two day summit. The conference speakers are experienced in establishing companies, developing them and raising finance, as well as selling them, and have many hard-won tips to impart.
In an exciting new panel session, attendees will have the chance to drive UK life sciences policy with the BIA. Following on from successes such as the patent box, ideas for new initiatives will be discussed in this interactive session and pulled together into a briefing to guide the BIA’s 2012 lobbying.
Nigel Gaymond, Chief Executive of the BIA, said:
“We all know how important it is to develop our expertise and network with peers in order to drive value creation at our organisations. The BIA 2011 Global BioLeadership Summit provides the perfect opportunity to do so, in the beautiful location of the Oakley Court Hotel in Windsor. Please make sure your organisation is represented at this industry-leading board-level summit.”
For further information, please contact Robert Winder, Communications Manager, 020 7565 7193; mobile 07825 942 934.
BIA Global BioLeadership Summit
The BIA Global BioLeadership Summit will be held on 6-7 October 2011 in Windsor. To register for the event and for more information visit http://www.bioindustry.org or contact Cathy Smyth csmyth@bioindustry.org
BioIndustry Association
Established in 1989, the BioIndustry Association (BIA) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies with whom such enterprise trades.
With over 250 members, the BIA supports a wide range of sectors, majoring on the human health benefits of the technology and represents the interests of these innovative companies to a broad section of stakeholders from patient groups to politicians, advancing its members interests both within the UK and internationally to create a healthy UK bioscience sector which benefits society. For further information, please go to: www.bioindustry.org
